This study was performed to assess the prevalence and genotypes of plasmid-borne extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in Escherichia coli in Korea. A total of 576 isolates of E. coli was collected from 12 Korean hospitals during May and July 2007. A phenotypic confirmatory test detected ESBLs in 82 (14.2 %) of the 576 E. coli isolates. The most common types of ESBLs identified were CTX-M-14 (n=32) and CTX-M-15 (n=27). The prevalence and diversity of the CTX-M mutants, including CTX-M-15, CTX-M-27 and CTX-M-57, with significant hydrolytic activity against ceftazidime were increased. PCR experiments detected genes encoding plasmid-borne AmpC β-lactamases in 15/56 cefoxitin-intermediate or cefoxitin-resistant isolates, and the most common type of AmpC β-lactamase identified was DHA-1 (n=10). These data suggest that the incidence of ESBLs in E. coli has increased as a result of the dissemination of CTX-M enzymes in Korea. In addition, CTX-M-22, CTX-M-27 and CTX-M-57 have appeared in Korea.
CLSI2006aMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically , 7th edn. approved standard M7–A7 Wayne, PA: Clinical and Laboratory Standards Institute;
CLSI2006bPerformance Standards for Antimicrobial Disk Susceptibility Tests , 9th edn. approved standard M2–A9 Wayne, PA: Clinical and Laboratory Standards Institute;
LeeK.,
LeeM.,
ShinJ. H.,
LeeM. H.,
KangS. H.,
ParkA. J.,
YongD.,
ChongY.2006; Prevalence of plasmid-mediated AmpC β -lactamases in Escherichia coli and Klebsiella pneumoniae in Korea. Microb Drug Resist 12:44–49[CrossRef]
PaiH.,
LyuS.,
LeeJ. H.,
KimJ.,
KwonY.,
KimJ. W.,
ChoeK. W.1999; Survey of extended-spectrum β -lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae : prevalence of TEM-52 in Korea. J Clin Microbiol 37:1758–1763
PoirelL.,
GniadkowskiM.,
NordmannP.2002; Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β -lactamase CTX-M-15 and of its structurally related β -lactamase CTX-M-3. J Antimicrob Chemother 50:1031–1034[CrossRef]
RossoliniG. M.,
D'AndreaM. M.,
MugnaioliC.2008; The spread of CTX-M-type extended-spectrum β -lactamases. Clin Microbiol Infect 14 (Suppl. 1):33–41[CrossRef]
RyooN. H.,
KimE. C.,
HongS. G.,
ParkY. J.,
LeeK.,
BaeI. K.,
SongE. H.,
JeongS. H.2005; Dissemination of SHV-12 and CTX-M-type extended-spectrum β -lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. J Antimicrob Chemother 56:698–702[CrossRef]
SongW.,
KimJ. S.,
KimH. S.,
YongD.,
JeongS. H.,
ParkM. J.,
LeeK. M.2006; Increasing trend in the prevalence of plasmid-mediated AmpC β -lactamases in Enterobacteriaceae lacking chromosomal ampC gene at a Korean university hospital from 2002 to 2004. Diagn Microbiol Infect Dis 55:219–224[CrossRef]
SongW.,
BaeI. K.,
LeeY. N.,
LeeC. H.,
LeeS. H.,
JeongS. H.2007; Detection of extended-spectrum β -lactamases by using boronic acid as an AmpC β -lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli
. J Clin Microbiol 45:1180–1184[CrossRef]
YanJ. J.,
HsuehP. R.,
LuJ. J.,
ChangF. Y.,
ShyrJ. M.,
WanJ. H.,
LiuY. C.,
ChuangY. C.,
YangY. C.other authors2006; Extended-spectrum β -lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan. Antimicrob Agents Chemother 50:1861–1864[CrossRef]